scispace - formally typeset
B

Beatriz Antón

Publications -  6
Citations -  16

Beatriz Antón is an academic researcher. The author has contributed to research in topics: Medicine & Bevacizumab. The author has an hindex of 1, co-authored 3 publications receiving 4 citations.

Papers
More filters
Journal ArticleDOI

miR-7, miR-10a and miR-143 Expression May Predict Response to Bevacizumab Plus Chemotherapy in Patients with Metastatic Colorectal Cancer

TL;DR: In this paper, the expression of 26 miRNAs were found to be associated with the effectiveness of bevacizumab plus chemotherapy, with progression-free survival (PFS), and with overall survival (OS) in metastatic colorectal cancer.
Journal ArticleDOI

Efficacy of bevacizumab-containing chemotherapy in metastatic colorectal cancer and CXCL5 expression: Six case reports

TL;DR: The main finding was that CXCL5 expression levels were several times higher in three patients with lower progression free survival from the start of treatment, which was observed in the three patients showing worse tumor response to treatment.
Journal ArticleDOI

FGFR1 Amplification and Response to Neoadjuvant Anti-HER2 Treatment in Early HER2-Positive Breast Cancer

TL;DR: Although based on a small sample size, the findings suggest that patients with FGFR1 amplification might benefit less from anti-HER2 antibody therapy, compared with those who receive chemotherapy as neoadjuvant treatment.
Journal ArticleDOI

Genetic Variants of ANGPT1, CD39, FGF2 and MMP9 Linked to Clinical Outcome of Bevacizumab Plus Chemotherapy for Metastatic Colorectal Cancer.

TL;DR: In this article, 20 single nucleotide polymorphisms (SNPs) in 13 genes were examined to predict tumour response and clinical outcome measured as progression free survival (PFS) and overall survival (OS) in 57 patients with metastatic colorectal cancer (mCRC) given bevacizumab plus chemotherapy.